Latest news with #RothCapital
Yahoo
7 hours ago
- Business
- Yahoo
Roth Capital Hikes Verona Pharma's (VRNA) Price Target to $116 On COPD Market Prospects
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating. The adjustment follows remarks by Dr Frank Sciurba, who discussed unmet chronic obstructive pulmonary disease needs. A close up of a researcher in a laboratory, examining a new biopharmaceutical drug used to treat resistant bacterial infections. The doctor shared positive insights on the company's product Ohtuvayre, highlighting its complementary role in newly approved biologics. According to Roth Capital, the enhanced understanding of Verona Pharma's Ohtuvayre's distinctive efficacy and risk profile is already sparking greater interest among investors. Consequently, the research firm raised its price target in response to the increased attention and appreciation of Verona Pharma's offering. The research firm remains bullish about the company's growth potential. Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. It focuses on developing treatments for chronic obstructive pulmonary disease (COPD). They are known for their product, ensifentrine, an investigational, inhaled, small molecule that acts as a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), combining bronchodilator and anti-inflammatory properties. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio
Yahoo
20 hours ago
- Business
- Yahoo
Groupon price target raised to $39 from $35 at Northland
Northland analyst Bobby Brooks raised the firm's price target on Groupon (GRPN) to $39 from $35 and keeps an Outperform rating on the shares after the company announced what the firm calls 'an opportunistic and proactive financing transaction.' The newly issued 2030 notes meaningfully simplifies the company's capital structure and provides more flexibility, the analyst tells investors. This deal removes any balance sheet overhangs and is a continuation of the company's shift from 'defense to offense,' the analyst added. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on GRPN: Disclaimer & DisclosureReport an Issue Groupon price target raised to $47 from $33 at Roth Capital Groupon Announces New Convertible Senior Notes Issuance Groupon price target raised to $35 from $30 at Northland Groupon price target raised to $33 from $27 at Roth Capital Short Report: Bears questioning Cinemark, Groupon rallies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Roth ‘increasingly positive' about multiple expansion for Gogo
Roth Capital analyst Scott Searle maintains a Buy rating on Gogo (GOGO) with a $16.50 price target after the company confirmed its first successful end-to-end 5G call utilizing the GCT Semi chipset. The news 'continues to derisk' Gogo's 5G headwinds and places air-to-ground services on a path to return to growth in 2026, the analyst tells investors in a research note. Roth is are 'increasingly positive' about sustained growth and multiple expansion for Gogo. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on GOGO: Disclaimer & DisclosureReport an Issue Gogo's 5G Milestone and Strategic Ownership Drive Buy Rating Gogo completes first 5G end-to-end call Gogo Holds Annual Stockholders Meeting, Elects Directors Gogo to participate in a webinar with Roth MKM Short Report: Short interest in Clear Secure hits record high Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
6 days ago
- Business
- Business Insider
Lifezone Metals price target lowered to $8 from $14 at Roth Capital
Roth Capital lowered the firm's price target on Lifezone Metals (LZM) to $8 from $14 and keeps a Buy rating on the shares. The firm says an Initial Assessment on Lifezone's proposed Kabanga Project outlines one of the largest, low-cost, vertically integrated nickel producers, and the most environmentally friendly operation in the world. Polymetallic high grades and regional infrastructure improvements unlocked the project, the analyst tells investors in a research note. Roth believes the net asset value calculated in the initial assessment suggests the company could be carried-to-production.
Business Insider
14-06-2025
- Business
- Business Insider
D-Wave Quantum price target raised to $18 from $12 at Roth Capital
Roth Capital raised the firm's price target on D-Wave Quantum (QBTS) to $18 from $12 and keeps a Buy rating on the shares. The firm believes D-Wave has gained customer market interest in recent months and in doing so is expanding its revenue potential across both hosted service and hardware sale opportunities. Roth expects both commercial and AI-related customer interest to intensify in the coming quarters. Confident Investing Starts Here:
